Nektar Therapeutics (NKTR) reported second-quarter 2026 revenue of $10.1 million and a net loss of $40.6 million, or $1.23 per basic and diluted share. Revenue was $11.2 million and net loss was $41.6 million in the prior-year quarter.
Cash and marketable securities totaled $1.023 billion at June 30, 2026. The company said it initiated the first two global registrational Phase 3 ZENITH AD trials for rezpegaldesleukin in July.
- Second-quarter operating costs and expenses were $52.5 million, compared with $47.4 million a year earlier.
- R&D expense rose to $39.1 million from $29.9 million, while G&A expense fell to $12.8 million from $17.1 million.
- First-half revenue was $21.0 million, while the first-half net loss was $85.5 million, or $2.96 per basic and diluted share.
- Nektar said it plans to start a registrational Phase 3 alopecia areata study in early 2027 and expects initial Phase 3 data readouts in mid-2028.
$NKTR Insider Trading Activity
$NKTR insiders have traded $NKTR stock on the open market 10 times in the past 6 months. Of those trades, 0 have been purchases and 10 have been sales.
Here’s a breakdown of recent trading of $NKTR stock by insiders over the last 6 months:
- HOWARD W ROBIN (President & CEO) has made 0 purchases and 6 sales selling 20,867 shares for an estimated $1,275,021.
- JONATHAN ZALEVSKY (Chief R&D Officer) has made 0 purchases and 4 sales selling 11,598 shares for an estimated $760,058.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$NKTR Hedge Fund Activity
We have seen 152 institutional investors add shares of $NKTR stock to their portfolio, and 86 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- BLACKROCK, INC. added 2,249,201 shares (+324.7%) to their portfolio in Q2 2026, for an estimated $157,016,721
- TWO SEAS CAPITAL LP added 1,133,056 shares (+57.8%) to their portfolio in Q2 2026, for an estimated $79,098,639
- BVF INC/IL added 1,000,000 shares (+64.1%) to their portfolio in Q1 2026, for an estimated $71,950,000
- FMR LLC added 764,732 shares (+17.8%) to their portfolio in Q2 2026, for an estimated $53,385,940
- STATE STREET CORP added 664,952 shares (+271.7%) to their portfolio in Q2 2026, for an estimated $46,420,299
- GEODE CAPITAL MANAGEMENT, LLC added 534,511 shares (+154.1%) to their portfolio in Q2 2026, for an estimated $37,314,212
- TWO SIGMA INVESTMENTS, LP added 457,727 shares (+96.8%) to their portfolio in Q1 2026, for an estimated $32,933,457
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
